Inactive Instrument

Karo Pharma AB (publ)

KARO

SE0007464888

Karo Pharma Aktiebolag Announces Management Changes, Effective September 1, 2021

August 24, 2021 at 02:40 am

Karo Pharma Aktiebolag has appointed Matt Roberts as the new Chief Commercial Officer of Karo, replacing Magnus Nylén who has decided to pursue opportunities outside of Karo. Matt will start his new position on September 1, 2021.

Latest news about Karo Pharma AB (publ)

Karo Healthcare AB acquired Rights to the OTC brand Proctosedyl from Bayer Aktiengesellschaft.	03-05	CI
Karo Healthcare AB acquired Topical Lamisil Business from Haleon UK Holdings Ltd.	10-31	CI
Karo Healthcare AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-09-21	CI
Karo Healthcare AB agreed to acquire Topical Lamisil Business from Haleon UK Holdings Ltd. for approximately £240 million.	23-08-01	CI
Karo Healthcare Announces Management Appointments	23-07-04	CI
Karo Healthcare Limited Appoints Michael Kaltenborn as Chief Strategy Corporate Development Officer, Effective February 1, 2023	23-01-17	CI
Karo Pharma AB agreed to acquire of Six brands of Teva for DKK 84 million.	22-12-04	CI
Karo Intressenter AB completed the acquisition of remaining 13.6% stake in Karo Pharma AB (OM : KARO).	22-11-23	CI
EQT's Karo Intressenter Gains Control Of 97% Stake In Karo Pharma	22-11-22	MT
Karo Pharma Gets Approval to Delist from Nasdaq First North Growth Market	22-11-11	MT
Karo Pharma Files for Delisting from Nasdaq First North Growth Market	22-11-10	MT
Karo Pharma Suitor Karo Intressenter Further Extends Takeover Acceptance Period	22-10-11	MT
EQT-backed Karo Intressenter Starts Mandatory Redemption of Remaining Karo Pharma Shares	22-09-26	MT
Karo Pharma AB(OM:KARO) dropped from S&P Global BMI Index	22-09-26	CI
EQT-backed Karo Intressenter's $1.5 Billion Karo Pharma Takeover Becomes Unconditional	22-09-19	MT
Karo Pharma Receives Fairness Opinion From Nordea Bank Regarding EQT-controlled Karo Intressenter's Offer	22-08-26	MT
Karo Pharma Lands $1.6 Billion Takeover Offer From EQT-controlled Shareholder	22-08-16	MT
Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (OM : KARO) for SEK 2.2 billion.	22-08-15	CI
Karo Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-21	CI
Karo Pharma to Raise $262 Million in Rights Issue	22-04-19	MT
Reckitt Completes Sale of E45 Brand to Karo Pharma	22-04-01	MT
Karo Pharma AB (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc.	22-03-31	CI
Karo Pharma AB (OM:KARO) acquired Del Decus Enterprises Ltd.	22-03-27	CI
Karo Pharma AB(OM:KARO) dropped from OMX Nordic All-Share Index	22-03-25	CI
Karo Pharma Receives Approvals For $265 Million Rights Issue, Change Of Listing To Nasdaq First North Growth Market	22-03-23	MT

Chart Karo Pharma AB (publ)

Duration

Period

More charts

Company Profile

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company's pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB, MedCore AB and Medireduce AB as subsidiaries.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.69%	728B
NOVO NORDISK A/S	+33.81%	603B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	279B
ASTRAZENECA PLC	+16.06%	244B
NOVARTIS AG	+7.82%	207B
ROCHE HOLDING AG	-5.48%	205B
PFIZER, INC.	-0.35%	163B

Other Pharmaceuticals